Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

on behalf of the French Cooperative Thoracic Intergroup (IFCT)

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    76 Citations (Scopus)

    Résumé

    Background: EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database. Patients and methods: Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 stage IV patients. Results: EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type (exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR=0.76 (95% CI: 0.61-0.95), P=0.002; exon 20: HR=1.56 (95% CI: 1.02-2.38), P=0.004}. EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR=0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR=1.46 (95% CI: 0.96-2.21), P=0.07]. First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved progression-free survival versus chemotherapy [HR=0.67 (95% CI: 0.53-0.85), P=0.001]. OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients. Conclusion: EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.

    langue originaleAnglais
    Pages (de - à)2715-2724
    Nombre de pages10
    journalAnnals of Oncology
    Volume28
    Numéro de publication11
    Les DOIs
    étatPublié - 1 nov. 2017

    Contient cette citation